Veterinary Medicine - November 2007 - (Page L15)

FLEA BITE FACTS Q&A stacks of data often will not dissuade many. Orally administered, systemically active compounds often can alleviate many concerns of pet owners. Griffin: If a systemic product is confined to the internal tissues and not secreted onto the skin or hair, then the drug does not enter the environment on hair or skin. Topical acting insecticides have an environmental impact because hair and skin with the drug are shed into the environment. “I would prefer a systemically administered product for my own dogs if it had an excellent safety and efficacy profile.” —Dr. Peter J. Ihrke product. The FDA use guidelines can be altered if required to improve efficacy when done in a way accepted by the profession. Ihrke: FDA approval is perhaps viewed as being held to a higher standard than an EPA-approved product only. This would afford some owners a greater comfort index in using an FDA-approved systemic product. I FDA VS. EPA Blagburn: Flea control products are subjected to rigorous manufacturer testing to comply with approval policies and procedures mandated by the EPA or the Food and Drug Administration (FDA). Topical products that are not absorbed and exert their effects after application to the skin surface are approved under EPA guidelines. Topical, oral, or injectable products that exert their effects systemically are approved under FDA guidelines. FDAapproved veterinary products are usually prescription products and can only be purchased and dispensed by a licensed veterinarian. Griffin: In general, the EPA is mainly concerned about the impact the drug has on the environment and not the safety or efficacy for the pet. Also, the EPA rules for use are not recommendations—they’re rules. It is illegal to alter EPA rules of use to improve efficacy of a product in treating a pet’s disease. The FDA requires more testing to document safety and efficacy and requires strict labeling to follow their rules for not misrepresenting the References 1. McCoy CM, Dryden MW, Broce AB. Blood feeding dynamics of cat fleas in flea feeding chambers attached to cats, in Proceedings. 48th Annu Meet Am Assoc Vet Parasitol 2003:32. 2. Rust W, Dryden M. The biology, ecology and management of the cat flea. Ann Rev Entomol 1997;42:451-473. 3. Dryden M, Gaafar S. Blood consumption by the cat flea, Ctenocephalides felis (Siphonaptera: Pulicidae). J Med Entomol 1991;28: 394-400. 4. Dryden M. Laboratory and field evaluations of topical flea control products, in Proceedings. British Veterinary Dermatology Study Group. Birmingham, England; April 1998:14-17. 5. Franc M, Cadiergues MC. Antifeeding effect of several insecticidal formulations against Ctenocephalides felis on cats. Parasite 1998;5:83-86. 6. McCoy CM. Blood feeding dynamics of newly emerged cat fleas, Ctenocephalides felis (Bouché) (Siphonaptera: Pulicidae) in chambers attached to insecticide-treated and untreated cats. MS thesis. Kansas State University, April 17, 2006. 7. Path to high-quality care: Practical tips for improving compliance. Lakewood, Colo: AAHA Press, 2003. To view this publication online, visit www.advanstarvhc.com/c19 15 http://www.advanstarvhc.com/c19

Table of Contents Feed for the Digital Edition of Veterinary Medicine - November 2007

Veterinary Medicine - November 2007 Contents Leading Off The Veterinary Medicine Interview: Dr. Lila Miller Clinical Exposures Idea Exchange A Challenging Case: Uveitis and Secondary Glaucoma in a Cat Is it Immune-Mediated Neutropenia? Pimobendan Treatment in Dogs with Congestive Heart Failure CE Form Product Preview Advertiser Index Marketplace/Classifieds Mind Over Miller Special Supplement by Lilly: Flea Bite Facts Q&A

Veterinary Medicine - November 2007

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.